The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Swiss Biotech Report 2026: Strong performance with new records in revenues and investments in privately funded companies

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

Active fraud campaign — updated warning for Swiss Biotech Day 2026

We are tracking an ongoing and escalating fraud campaign targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

SIX Swiss Exchange talks to: BioVersys on how it is turning scientific excellence into investor confidence

Fabian Gerber, SIX Swiss Exchange
SIX Swiss Exchange reviews publicly listed companies included in 'Highlights of 2025: Year in Review' (see PDF edition, pages 56 to 59). This year it recognizes the notable success of BioVersys, which has rapidly grown from an ETH spin-off to become the first SIX biotech IPO since 2018.
May 5, 2026

TechBio talent & tenacity: driving Switzerland's next wave of innovation

Samantha Paoletti & Gilles Weder, CSEM
For the 15th consecutive year, Switzerland tops the Global Innovation Index (GII), leading globally in knowledge and technology outputs and creative industries, even amid global R&D and venture capital headwinds. This sustained performance reflects a powerful mix of exceptional talent, deep collaboration, and long-term commitment to innovation.
May 5, 2026

From discovery to commercial HQ: Switzerland's talent advantage

Sirpa Tsimal, Swiss Global Enterprise
Switzerland's strength as a global biotech hub is often described in terms of innovation, productivity, and quality. At the heart of all three lies a decisive factor: talent. From early scientific discovery to large-scale manufacturing and global commercial leadership, Switzerland offers a talent ecosystem that supports the entire biotech value chain.
May 5, 2026

Switzerland as a global biomanufacturing hub

Jan Lucht, scienceindustries
Switzerland is the chosen location of a large number of world-class biomanufacturing facilities. In addition to its strong focus on therapeutics and drug products, Switzerland's biomanufacturing sector extends beyond the pharmaceutical industry. Strong talent, innovation, collaboration, and long-term strategy are some of the factors that underpin Switzerland's global impact.
May 5, 2026